Monocyte-derived dendritic cells express and secrete matrix-degrading metalloproteinases and their inhibitors and are imbalanced in multiple sclerosis

Journal of Neuroimmunology

Volumn 126, Issue 1-2, 2002, Pages 161-171

  Kouwenhoven, Mathilde ^a   Özenci, Volkan ^a   Tjernlund, Annelie ^a   Pashenkov, Mikhail ^a   Homman, Mohammed ^b   Press, Rayomand ^a   Link, Hans ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dendritic cells (DC); Matrix degrading metalloproteinases (MMP); Multiple sclerosis (MS); Tissue inhibitors of MMP (TIMP)

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MESSENGER RNA; MONOCLONAL ANTIBODY; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; CELL FUNCTION; CELL MIGRATION; CELL SECRETION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME RELEASE; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT; WESTERN BLOTTING; ZYMOGRAPHY;

ADULT; CELL MOVEMENT; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 0036090821     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(02)00054-1     Document Type: Article

References (45)

1. Dendritic cells and the control of immunity
2. Immunobiology of dendritic cells
3. Interferon-beta inhibits Th1 responses at the dendritic cell level. Relevance to multiple sclerosis
4. Matrix metalloproteinases degrade myelin basic protein
5. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor
6. Expression of matrix metalloproteinases by human plasma cells and B-lymphocytes
7. The matrix metalloproteinases and their natural inhibitors: Prospects for treating degenerative tissue diseases
8. Monocyte-derived dendritic cells: A potential target for the therapy in multiple sclerosis (MS)
9. Processing of tumour necrosis factor-alpha precursor by metalloproteinases
10. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
11. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system
12. Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines
13. Multiple sclerosis: Elevated expression of matrix metalloproteinases in blood monocytes
14. Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke
15. The instructive role of dendritic cells on T cell responses: Lineages, plasticity and kinetics
16. Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood
17. T cell gelatinases mediate basement membrane transmigration in vitro
18. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis
19. Organ-specific autoantigens induce interferon-gamma and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis
20. Dendritic cells in experimental allergic encephalomyelitis and multiple sclerosis
21. Vaccination with autologous dendritic cells: From experimental autoimmune encephalomyelitis to multiple sclerosis
22. Introduction: TH2-inducing DC2 for immunotherapy
23. Dendritic cell lineage, plasticity and cross-regulation
24. Cell migration in the immune system: The evolving inter-related roles of adhesion molecules and proteinases
25. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions
26. The matrix degrading metalloproteinases
27. Cytokine regulation of metalloproteinase gene expression
28. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
29. Metalloproteinases and their tissue inhibitors in multiple sclerosis
30. Cytolysis of human dendritic cells by autologous lymphokine-activated killer cells: Participation of both T cells and NK cells in the killing
31. Two subsets of dendritic cells are present in human cerebrospinal fluid
32. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
33. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein
34. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators
35. Matrix metalloproteinases in wound repair (review)
36. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease
37. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by human-granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor alpha
38. The complete primary structure of human matrix metalloproteinase-3. Identity with stromyelisin
39. Metalloproteinase profile of human dendritic cells: Selective upregulation of gelatinase-B during GM-CSF+IL-4 driven development from peripheral blood precursors
40. Chemokines and dendritic cell traffic
41. Dendritic cell development and maturation
42. The cell biology of antigen presentation in dendritic cells
43. Matrix metalloproteinase inhibition. From the Jurassic to the third millennium
44. Matrix metalloproteinases and diseases of the CNS
45. Comparison of techniques for measurement of gelatinases/type IV collagenases: Enzyme-linked immunoassays versus substrate degradation assays